Search results for "Lipid control"

showing 2 items of 2 documents

Documento de consenso de la Sociedad Española de Arteriosclerosis (SEA) para la prevención y tratamiento de la enfermedad cardiovascular en la diabet…

2018

Este artículo se encuentra disponible en la siguiente URL: https://www.elsevier.es/es-revista-clinica-e-investigacion-arteriosclerosis-15-articulo-documento-consenso-sociedad-espanola-arteriosclerosis-S0214916818300846 This is the pre-peer reviewed version of the following article: Ruiz-García, A., Arranz-Martínez, E., Morón-Merchante, I., Pascual-Fuster, V., Tamarit, JJ., Trias-Villagut, F. et al. (2018). Documento de consenso de la Sociedad Española de Arteriosclerosis (SEA) para la prevención y tratamiento de la enfermedad cardiovascular en la diabetes mellitus tipo 2. Clínica e Investigación en Arteriosclerosis, vol. 30, supl. 1 (julio), pp. 1-19, which has been published in final form …

Blood pressure controlmedicine.medical_specialtyHipertensión.FarmacologíaEnfermedad cardiovascularDisease030204 cardiovascular system & hematologyDiabetes - Farmacoterapia.Enfermedades cardiovasculares - Factores de riesgo - Tratamiento.Diabetes - Chemotherapy.03 medical and health sciencesTratamiento médicoCardiovascular system - Diseases - Risk factors - Treatment.0302 clinical medicineDiabetes mellitusHypertension.MedicinePharmacology (medical)Lipid controlHypoglycemic drugs030212 general & internal medicineIntensive care medicineInhibidores de agregación plaquetariabusiness.industryHypertriglyceridemiaType 2 Diabetes Mellitusnutritional and metabolic diseasesArteriosclerosismedicine.diseaseDiabetes mellitus tipo 2Cardiology and Cardiovascular Medicinebusiness
researchProduct

Importancia de la dislipidemia en la enfermedad cardiovascular: un punto de vista

2015

The authors present their view on the prevention of cardiovascular diseases, accepting the European ESC/EAS guidelines. They consider that the aim of the lipid control, based on LDL-C goals, is essential for the prevention and treatment of cardiovascular diseases. In subjects with metabolic syndrome (mainly, abdominal obesity, pre-diabetes and diabetes), the primary objective should be apoB or Non-HDL-C, which are better associated with cardiovascular risk. The treatment must be lifestyle changes and control of other risk factors. After calculating cardiovascular risk, statins are the first therapeutic step, with the strength and dose needed to achieve LDL-C goals. If targets are not achiev…

medicine.medical_specialtybusiness.industryDiseaseArteriosclerosismedicine.diseaseEzetimibeAge groupsDiabetes mellitusInternal medicinemedicinelipids (amino acids peptides and proteins)Pharmacology (medical)Lipid controlmedicine.symptomMetabolic syndromeCardiology and Cardiovascular MedicinebusinessAbdominal obesitymedicine.drugClínica e Investigación en Arteriosclerosis
researchProduct